SCHEMBL5478102

SCHEMBL5478102

Cn1cc2c(n1)NC(=O)C2(c1ccc(NS(C)(=O)=O)cc1)c1ccc(NS(C)(=O)=O)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.38
PGR P06401 2/20 0.38
ALDH1A1 P00352 4/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
KDM4E B2RXH2 2/20 0.36
HPGD P15428 2/20 0.36
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.36
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA9 Q16790 1/20 0.35
BRD4 O60885 1/20 0.34
KIF11 P52732 1/20 0.34
BRPF1 P55201 1/20 0.34
PTGS2 P35354 2/20 0.34
TDP2 O95551 1/20 0.34
DHX9 Q08211 1/20 0.34
GAA P10253 1/20 0.34
HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5478070 0.80 ADORA3 (0.48) SMN1; SMN2KDM4ELMNAHTTGAA
SCHEMBL5483547 0.74 SMN1; SMN2 (0.37) KEAP1PGRALDH1A1SMN1; SMN2KDM4E
SCHEMBL5482310 0.69 SMN1; SMN2 (0.38) KEAP1PGRALDH1A1SMN1; SMN2KDM4E
SCHEMBL5482451 0.69 SMN1; SMN2 (0.38) KEAP1PGRALDH1A1SMN1; SMN2KDM4E
SCHEMBL5480164 0.69 KIF11 (0.38) KEAP1PGRALDH1A1SMN1; SMN2KDM4E
SCHEMBL5474271 0.67 KIF11 (0.40) KEAP1PGRALDH1A1SMN1; SMN2KDM4E
SCHEMBL5482571 0.67 KIF11 (0.40) KEAP1PGRALDH1A1SMN1; SMN2KDM4E
SCHEMBL5480073 0.66 MET (0.44) KEAP1PGRSMN1; SMN2HTTKCNH2
SCHEMBL5478650 0.64 KIF11 (0.38) KEAP1PGRALDH1A1SMN1; SMN2KDM4E
SCHEMBL12054668 0.64 KEAP1 (0.75) KEAP1PGRALDH1A1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US disclosed
EP-1734951-A2 DIPHENYL-INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TopoTarget A/S (DK) 2006-12-27 EP disclosed
WO-2005097107-A2 DIPHENYL - INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TOPOTARGET A/S (DK) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer MTOR, RICTOR, CDK4 KEAP1 1542/4885PGR 879/4885ALDH1A1 2650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.